Leukocyte immunoglobulin-like receptor: Difference between revisions
Michal Harel (talk | contribs) No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
| Line 2: | Line 2: | ||
'''Leukocyte immunoglobulin-like receptors''' (LIR) or '''CD85''' have extracellular immunoglobulin domains. LIR modulates a variety of immune cells. LIR interacts with class I MHC molecules<ref>PMID:19548123</ref>. <scene name='55/552188/Cv/6'>Leukocyte immunoglobulin-like receptor complex with class I MHC, β-2 microglobulin and POL polyprotein peptide</scene> (PDB entry [[1p7q]]). <scene name='55/552188/Cv/7'>Interactions between LIR and class I MHC, β-2 microglobulin</scene>. | '''Leukocyte immunoglobulin-like receptors''' (LIR) or '''CD85''' have extracellular immunoglobulin domains. LIR modulates a variety of immune cells. LIR interacts with class I MHC molecules<ref>PMID:19548123</ref>. <scene name='55/552188/Cv/6'>Leukocyte immunoglobulin-like receptor complex with class I MHC, β-2 microglobulin and POL polyprotein peptide</scene> (PDB entry [[1p7q]]). <scene name='55/552188/Cv/7'>Interactions between LIR and class I MHC, β-2 microglobulin</scene>. | ||
*'''LILRA2''' is an activating receptor that inhibits dendritic cell differentiation. | |||
*'''LILRA5''' has a role in triggering innate immune responses. | |||
*'''LILRB1''' interacts with classical and non-classical human leukocyte antigen (HLA) class I molecules<ref>PMID:37781391</ref>. | |||
See also: | See also: | ||